Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
PSM retrospective 220,517 patients in Brazil,133,051 taking ivermectin as part of a citywide prophylaxis program, showing significantly lower hospitalization and mortality with treatment. CAAE:47124221.2.0000.5485.
Additional results are presented here:
[odysee.com], including improved efficacy with analysis based on irregular/regular use, and a strong dose-response relationship.
Confirmation from independent analysis of the raw data:
[].
risk of death, 70.0% lower, RR 0.30, p < 0.001, treatment 25 of 3,034 (0.8%), control 79 of 3,034 (2.6%), NNT 56, adjusted per study, multivariate linear regression, propensity score matching.
|
risk of hospitalization, 67.0% lower, RR 0.33, p < 0.001, treatment 44 of 3,034 (1.5%), control 99 of 3,034 (3.3%), adjusted per study, multivariate linear regression, propensity score matching.
|
risk of case, 44.5% lower, RR 0.56, p < 0.001, treatment 4,197 of 113,845 (3.7%), control 3,034 of 45,716 (6.6%), NNT 34.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Kerr et al., 12/11/2021, retrospective, propensity score matching, Brazil, South America, peer-reviewed, 9 authors, study period July 2020 - December 2020, dosage 200μg/kg days 1, 2, 16, 17, 0.2mg/kg/day for 2 days every 15 days.